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Abstract
Hematopoietic reconstitution, following bone marrow or stem cell transplantation, requires a microenvironment niche
capable of supporting both immature progenitors and stem cells with the capacity to differentiate and expand. Osteoblasts
comprise one important component of this niche. We determined that treatment of human primary osteoblasts (HOB) with
melphalan or VP-16 resulted in increased phospho-Smad2, consistent with increased TGF-b1 activity. This increase was
coincident with reduced HOB capacity to support immature B lineage cell chemotaxis and adherence. The supportive deficit
was not limited to committed progenitor cells, as human embryonic stem cells (hESC) or human CD34+ bone marrow cells
co-cultured with HOB pre-exposed to melphalan, VP-16 or rTGF-b1 had profiles distinct from the same populations cocultured with untreated HOB. Functional support deficits were downstream of changes in HOB gene expression profiles
following chemotherapy exposure. Melphalan and VP-16 induced damage of HOB suggests vulnerability of this critical niche
to therapeutic agents frequently utilized in pre-transplant regimens and suggests that dose escalated chemotherapy may
contribute to post-transplantation hematopoietic deficits by damaging structural components of this supportive niche.
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describing BMSC have shown that damage by chemotherapy and
radiotherapy can affect the ability of the BMSC to self-repair and
leads to decreased numbers of functional immune system cells in
the blood, with deficits persisting years after transplant [9,10]. The
effects of chemotherapy on HOB have been studied in some detail
by other groups, but not the extent of BMSC. Studies by Davies et
al. used both osteoblast-like cell lines and osteoprogenitor cell lines
and showed that exposure of these cells to chemotherapeutic
agents led to decreased cell numbers, and interestingly, osteoprogenitor cells appeared to be deleted preferentially [11]. Davies et
al. also demonstrated that combination chemotherapy commonly
used in the treatment of childhood malignancies led to decreased
HOB numbers, which could be restored by administering
glucocorticoids [12]. Using a rat model, Xian et al. studied the
effects of methotrexate on bone growth and they observed that
methotrexate exposure led to many different types of bone
damage, but this affect could be abrogated with the addition of
folinic acid, which promoted proliferation of osteoblast progenitors
[13]. Finally, Fan et al. described how different chemotherapeutic
agents affect bone growth differently and described the implica-

Introduction
The stem cell niche hypothesis was first presented in 1978 by
Schofield who suggested that stem cells were associated with
accessory cells that influence their behavior [1]. Studies from
several labs have expanded our appreciation of the unique
anatomical niches within the marrow microenvironment and have
characterized areas of optimal stem cell support [2]. The niche’s
cellular components consist of osteoblasts (HOB), bone marrow
stromal or mesenchymal stem cells (BMSC, MSC), and endothelial cells [3,4]. Recent work has demonstrated the importance of
the interaction of HOB and stem cells in the niche, suggesting that
hematopoietic stem cells (HSC) can regulate MSC differentiation
into HOB and that they, in turn, play an important role in the
support of B lymphocytes and differentiation of HSCs [5,6].
Additionally, it has been shown that resting HSCs are maintained
in a quiescent state as a result of their close proximity to HOB and
that the number of HSCs change as a result of the number and
type of HOB present [7,8], highlighting the potential for
hematopoietic deficiencies if HOB function is altered. Studies
PLoS ONE | www.plosone.org
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Carlsbad, CA) 2 mM L-glutamine (Mediatech), 0.05 mM 2mercaptoethanol (Sigma-Aldrich, St. Louis, MO), non-essential
amino acids and B-FGF solution. H9 cells were moved to HOB
feeder layers where indicated. CD34+ bone marrow cells
(ALLCELLS, Emeryville, CA) were grown in RPMI-1640 supplemented with 10% fetal bovine serum. Melphalan (Sigma-Aldrich)
was reconstituted at a stock concentration of 50 mg/ml immediately prior to use. VP-16 (Etoposide, Bristol Myers Squibb, New
York, NY) was stored at a concentration of 33.98 mM and diluted
immediately prior to use. Human rTGF-b1 (R&D, Minneapolis,
MN) was used at a concentration of 10 ng/ml. Human rIL-3 (R&D)
was used at a concentration of [100 ng/ml].

tions that using these agents in combination might have posttherapy [14]. While these studies have focused on the affects of
chemotherapy on bone growth and recovery, most have not
investigated how this chemotherapy-induced damage to HOB
affects HSC and progenitor cell recovery and support following
transplantation and further investigation is warranted.
The stem cell niche is characterized, in part, by expression of
specific cytokines, including TGF-b and CXCL-12, to facilitate
signaling between the niche components and HSC. Studies have
demonstrated that chemotherapy increases the levels of active
TGF-b1 resulting in decreased ability of BMSC to support HSC
[15,16]. It has also been shown that TGF-b1 has crosstalk with
CXCL-12 and can stimulate the differentiation of progenitor cells
to erythroid and myeloid cells resulting in a deficit of the primitive
stem cell pool [17]. The importance of CXCL-12 is emphasized,
in part by its requirement for homing of progenitor cells to the
bone marrow following transplantation [18,19]. We have
previously demonstrated that diminished levels of CXCL-12 in
the supernatants of VP-16 treated BMSC results in the loss of an
optimal chemokine gradient to which CXCR-4+ pro-B cells
respond with CXCL-12, subsequently shown to also be important
in regulation of stem cell phenotype by Guo et al. [20,21].
Sugiyama et al. showed that mice deficient in the CXCL-12
receptor, CXCR-4, had a reduction in HSC, in both vascular and
endosteal niches, and increased sensitivity to myelotoxic stress
compared to their wild-type counterparts [22]. Other studies of
CXCR-4 in the HSC niche have shown that CXCR-4 is essential
to maintain quiescence and retention of stem cells [23].
In the current study, we investigated melphalan and VP-16
induced damage to HOB with emphasis on CXCL-12 and TGF-b1
levels following exposure to chemotherapeutic agents, and the
implications of this damage on hematopoietic reconstitution. Global
changes in HOB gene expression in response to melphalan were
investigated to determine the vulnerability of HOB to genotoxic
stress. In addition, TGF-b1, CXCL-12 and VCAM-1 were
investigated as representative HOB proteins involved in three
critical functions of the endosteal niche; support of pluripotency,
homing and stem cell retention [24,25]. Our results indicate diverse
changes in gene expression profiles following HOB exposure to
melphalan, conditioned media from BMSC pre-treated with
melphalan, and following exposure to rTGF-b1 as one of the
factors elaborated by chemotherapy damaged BMSC [15].
Coincident with altered gene expression profiles, HOB exposed to
chemotherapeutic agents or rTGF-b1 had increased levels of active
TGF-b1, altered support of differentiation of CD34+ bone marrow
cells, reduced ability to support Oct-4 positive embryonic stem cell
colonies, and reduced chemotactic support and adhesion of CXCR4+ pro-B cells. These data suggest that the niche in which
hematopoietic recovery occurs following transplantation may be
more vulnerable to damage than previously appreciated.

Adhesion assay
HOB were pre-exposed to melphalan [50 mg/ml], VP-16
[50 mM], or rTGF-b1 [10 ng/ml] for 24 hours. C1.92 pro-B cells
were stained with CellTrackerTM Green CMFDA (Invitrogen)
according to the manufacturer’s instructions. The HOB adherent
layer was thoroughly rinsed following treatment and fluorescently
labeled C1.92 pro-B cells (16105) were added in co-culture for
4 hours. Subsequently, the media containing non-adherent C1.92
was aspirated and the cultures were gently rinsed. Remaining
HOB and adherent C1.92 were trypsinized and C1.92 cells were
enumerated using a FACSCalibur flow cytometer (BD, Franklin
Lakes, NJ) with events counted for 30 seconds on high flow rate.
Data were analyzed using WinMDI software.

Chemotaxis assays
HOB were plated in the bottom chamber of a transwell at 100%
confluence and were left either untreated or exposed to melphalan
[50 mg/ml], VP-16 [50 mM], or rTGF-b1 [10 ng/ml] for 24 hours.
After 24 hours, 350 mL of supernatant was placed in the bottom of a
transwell and JM-1 cells (16106 cells/ml) were added to the top
chamber, and incubated at 37uC for 4 hours. JM-1 cells migrated
through the 5 mm pores to the bottom chamber towards media
supplemented with 100 ng/mL CXCL-12 (positive control), media
alone (negative control), or media conditioned by untreated HOB or
HOB exposed to melphalan, VP-16 or rTGF-b1 with and without
rCXCL-12 [1 ng/ml], which was added prior to addition of CXCR4+ cells to the top chamber. Cells were collected using a FACSCalibur
flow cytometer (BD) with events counted for 30 seconds on high flow
rate. Data were analyzed by WinMDI software.

Colony Assays
To complete colony assays, HOB were left untreated or exposed to
melphalan [50 mg/ml] or rTGF-b1 [10 ng/ml] for 24 hours.
Following exposure, HOB layers were rinsed and CD34+ bone
marrow cells (1.756105) were added in co-culture supplemented with
recombinant IL-3 [100 ng/ml] for 48 hours. CD34+ cells were
collected, viability determined, and 16103 viable cells added to
Methocult-Classic (Stem Cell Technologies) (supplemented with
rhSCF, rhGM-SCF, rhIL-3 and rhErythropoietin for myeloid
lineage) in triplicate. Colonies were counted and scored after 7 days
in culture.

Materials and Methods
Cell Lines and Reagents
Human osteoblasts (HOB) were purchased from Promocell
(Heidelberg, Germany) and maintained in osteoblast growth media.
The CXCR-4+/VLA-4+ pre-pro-B leukemic cell line JM-1 was
purchased from the ATCC (CRL-10423, Manassas, VA). The
BMSC and IL-7 dependent murine pro-B cell line C1.92 was kindly
provided by Dr. Kenneth Landreth and has been described in detail
[26]. Human embryonic stem cells (H9, WiCell, Madison WI) were
maintained on irradiated mouse embryo fibroblasts (MEF) and
grown in DMEM-F12 media (Mediatech, Manassas, VA) supplemented with Knockout Serum Replacement (Gibco/Invitrogen,
PLoS ONE | www.plosone.org

ELISA
To complete the CXCL-12 ELISA (R&D), HOB were plated
at 100% confluence and left untreated or exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for
24 hours. The media was then removed, cells were rinsed, fresh
media added and allowed to condition for 48, 72 or 96 hours posttreatment. Supernatants were collected and a CXCL-12 ELISA
completed. The TGF-b1 ELISA (R&D) was completed using
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to melphalan [50 mg/ml] for 24 hours) for 6 hours. Total RNA
was isolated from HOB using the RNeasy RNA isolation kit
(Qiagen,Valencia, CA) with quality assessed by electrophoretic
analysis on an Agilent Model 2100 Bioanalyzer. RNA samples had
integrity numbers greater than 8.0 (8.4–10). RNA (250 ng) was
used as the template for synthesis of internally labeled cRNAs
using the Agilent QuickAmp Labeling kit and cyanine 3-CTP and
cyanine 5-CTP (Perkin Elmer, Waltham, MA) and a modified
QuickAmp protocol [27]. A total of 825 ng of cyanine 3- and
cyanine5-labeled cRNAs was combined and hybridized onto
Agilent Whole Human Genome 4644 K microarrays at 65uC for
17 hours and washed according to the manufacturer’s protocol.
Slides were scanned on an Agilent DNA Microarray Scanner.
HOB exposed to rTGF-b1 and conditioned media were
competitively hybridized against untreated HOB in a balanced
block design with six replicates. HOB exposed to melphalan and
untreated HOB were hybridized against Stratagene Universal
Reference RNA (Agilent Technologies, Santa Clara, CA) in a
universal reference design with four replicates.
Intersections of groups and corresponding statistically significant
fold changes (details described in the supplemental section) for
each experiment were imported into Ingenuity Pathway Analysis
(IPA) software v 2.6 (Ingenuity Systems H, Redwood City, CA,
www.ingenuity.com). A core analysis was performed in IPA, using
default settings, to search for networks associated with these lists of
genes. MIAME compliant complete microarray data may be
accessed at the NCBI Gene Expression Omnibus (GEO) database
(GSE17860).

HOB plated at 100% confluence in serum free media and left
untreated or exposed to rTGF-b1 [10 ng/ml] for 24 hours. The
media was removed, cells were rinsed, and fresh serum-free media
was added to each well. After 24 hours, supernatants were
collected and a TGF-b1 ELISA completed.

Fluorescent Microscopy
HOB were cultured on coverslips and left untreated or exposed to
melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for
24 hours, washed thoroughly and H9 stem cells added. Co-cultures
were monitored daily and upon colony formation, counts based on
colony morphology were completed. Coverslips were subsequently
stained for Oct-4. To complete intracellular staining, cells were
fixed in 4% paraformaldehyde and permeabilized with 0.5%
Triton-X-100. After blocking for 30 minutes in 5% BSA/1X PBS,
cells were incubated with mouse a-human primary antibody (1 mg),
specific for human Oct-4 (Millipore) or matched isotype control, in
5% BSA/1X PBS for 1 hour at RT. Coverslips were washed with
1X PBS, incubated with Alexa FluorTM 488 labeled secondary amouse antibody (1 mg) at RT for 1 hour and mounted on glass
microscope slides with ProLongTM Gold plus DAPI (Invitrogen).
Confocal images were acquired using a Zeiss LSM510 confocal
system connected to a Zeiss AxioImager microscope (Thornwood,
NY). Photographs of human embryonic stem cells were taken using
a Nikon Coolpix 990 camera. To complete phospho-Smad2
staining, HOB cells were plated on coverslips and left untreated
or exposed to melphalan [100 mg/ml] or VP-16 [100 mM] for
4 hours. Staining and imaging was completed as described above
using a murine primary antibody (1.5 mg/coverslip), specific for
human phospho-Smad2 (Cell Signaling Technology Inc., Danvers,
MA) or matched isotype control.

Real Time Reverse Transcriptase PCR
Total cellular RNA was isolated from HOB using the RNeasy
RNA isolation kit (Qiagen). Real time RT-PCR was performed
using 50 ng RNA per reaction using the QuantiTech SYBR
Green RT-PCR kit (Qiagen). Primers specific for human CXCL12 were obtained from SuperArray (Frederick, MD) with 0.25 ml
used per reaction. Primers specific for TGF-b1 and the
housekeeping gene (HPRT-1) were purchased from Real Time
Primers, LLC (Elkins Park, PA). Samples were analyzed in
triplicate using the Applied Biosystems 7500 Real-time PCR
system (Foster City, CA). Amplification parameters included 50uC
for 30 minutes, 95uC for 15 minutes, 94uC for 15 seconds (645
cycles), 58uC for 30 seconds, and 72uC for 45 seconds. Changes in
gene expression were determined using the Comparative Ct
method and analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method [28].

HOB and CD34+ cell co-culture
HOB were grown to confluence and were left untreated or
exposed to melphalan [25 mg/ml] or rTGF-b1 [10 ng/ml] for
24 hrs. Following treatment, HOB were rinsed and human
CD34+ bone marrow cells were added. Cultures were supplemented with recombinant IL-3 (100 ng/ml) every 2 days. CD34+
bone marrow cells were collected after 48 hours in co-culture.
Viability was determined and staining for the following cell surface
makers was completed using the indicated antibodies: phycoerythrin (PE)–conjugated CD4 (clone SK3), CD19 (4G7), phycoerythrin-Cy7 (PE-Cy7)–conjugated CD56 (NCAM16.2), CD34
(8G12), peridinin-chlorophyll protein-Cy5.5 (PerCP-Cy5.5)–conjugated CD3 (SK7), CD33 (P67.6), fluorescein isothiocyanate
(FITC)–conjugated CD8 (SK1), CD71 (L01.1), allophycocyanin
(APC)–conjugated CD14 (MQP9), CD3 (SK7), and allophycocyanin-Cy7 (APC-Cy7)–conjugated CD45 (2D1) ([BD], San Jose,
CA). The samples were stained in the following combinations:
isotype controls and CD45, CD45, CD34, CD3, CD19, CD33,
and CD71 and CD45, CD3, CD4, CD8, CD56, and CD14. Data
were acquired with a FACSCanto II (BD) flow cytometer with a
minimum of 30,000 events for each sample and analyzed with
FACSDiva software (BD). Initial gating was based on forward
(FSC)/side scatter (SSC) to exclude debris and non-viable events.
Thresholds for positivity were set such that greater than 99% of
events within the gated region were negative for each isotypematched control antibody. Positive events were back-gated to
ensure that they constituted a discrete population by CD45/SSC,
confirming specificity of antigen binding.

Western Blot Analysis
HOB were grown to confluence and left untreated or exposed to
melphalan [100 mg/ml], VP-16 [100 mM] or rTGF-b1 [10 ng/
ml] with or without SB 431542 [10 mM] for 4 hours. Following
treatment, cells were collected and protein isolated and quantitated. Western blot analysis was completed and probed using
antibodies specific for P-Smad2 (Cell Signaling), total Smad-2
(Cell Signaling) and anti-rabbit-HRP (Santa Cruz Biotechnology,
Santa Cruz, CA). Proteins were visualized using Immobilon
Western ECL reagents (Millipore). Quantitation was completed
using Image J software.

Statistics
Data were analyzed using the Students–t test or ANOVA where
appropriate with statistical significance of p#.05 denoted by an
asterisk (*). Microarray data analysis is described in the supplemental section.

Microarray
HOB were left untreated or exposed to melphalan [50 mg/ml],
rTGF-b1 [10 ng/ml] or conditioned media from BMSC (exposed
PLoS ONE | www.plosone.org
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patients even after 12 years, suggesting that the damage of
supportive cells of the bone marrow is sustained [30].
To determine if direct exposure of HOB to chemotherapeutic
agents resulted in increased levels of active TGF-b1, HOB were
exposed to melphalan or VP-16 and the expression of total and
active TGF-b1 was assessed. Direct exposure of HOB to
chemotherapeutic agents (Figure 1A) does not alter the expression
of TGF-b1 mRNA. In contrast, exposure of HOB to melphalan or
VP-16 (Figure 1B) and melphalan, VP-16 or rTGF-b1 (Figure 1C)
resulted in increased active TGF-b1 reflected by increased
phosphorylation of Smad2 protein visualized by confocal micros-

Results
Melphalan and VP-16 exposure of HOB increases the
levels of active TGF-b1
Earlier observations suggested that BMSC exposed to chemotherapy have higher levels of active TGF-b1 and diminished
capacity to support pro-B cells and normal hematopoiesis [15–
17,29]. Additionally, retrospective studies of patients that received
allogeneic bone marrow transplants showed that they have serious
and irreversible stromal damage as measured by CFU-F
frequencies that did not recover to the levels of normal control

Figure 1. Melphalan and VP-16 exposure of HOB increases the level of active TGF-b1. A) HOB were exposed to melphalan [50 mg/ml] or
VP-16 [50 mM] for 24 hours and real time PCR for TGF-b1 completed. B) HOB were exposed to melphalan [100 mg/ml] or VP-16 [100 mM] for 4 hours,
fixed and stained for detection of phospho-Smad2 (green), as a read-out of TGF-b1 activity (DAPI stain for nuclei-blue). C) HOB were exposed to
melphalan [100 mg/ml], VP-16 [100 mM] or rTGF-b1 [10 ng/ml] with or without SB 431542 [10 mM] for 4 hours and a western blot completed for pSmad2 and total Smad2. P-Smad2 expression was normalized to total Smad2 expression. D) HOB were exposed to rTGF-b1 [10 ng/ml] for 24 hours
and real time PCR completed (left). Additionally, HOB were exposed to rTGF-b1 [10 ng/ml] for 24 hours, the HOB layer was rinsed and new media was
added and allowed to condition for 24 hours before being evaluated by ELISA to quantitate the amount of secreted TGF-b1 (right). (NT = No
Treatment, Mel = melphalan, VP = VP-16, TGF = rTGF-b1, SB = SB 431542).
doi:10.1371/journal.pone.0030758.g001
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copy (Figure 1B) and western blot analysis (Figure 1C). To
determine if the increase in TGF-b1 signaling and Smad2
phosphorylation was due to increased TGF-b1 induced by the
chemotherapeutic agents, SB 431542, a selective inhibitor of TGFb1 receptor kinases was used in combination with melphalan, VP16 or rTGF-b1 exposure. SB 431542 was able to inhibit both the
basal phosphorylation of Smad2 as well as the increase in Smad2
phosphorylation induced by melphalan or VP-16 exposure. Direct
exposure of HOB to rTGF-b1 (Figure 1D) increased both TGF-b1
mRNA and protein expression. To mimic the indirect effects of
soluble cues elaborated by damaged stroma on HOB, BMSC were
exposed to melphalan or VP-16, rinsed, and allowed to condition
media that was then placed on HOB that had not been exposed to
chemotherapeutic agents. HOB exposed to conditioned media
from damaged BMSC have increased levels of phosphorylated
Smad2 when compared to their counterparts exposed to
conditioned media from untreated stroma (data not shown).

Pre-exposure of HOB to chemotherapeutic agents or
rTGF-b1 alters the ability of HOB to support
hematopoietic progenitors
One of the critical functions of HOB in the endosteal niche is to
support stem cells for appropriate hematopoietic reconstitution to
occur post-transplantation [31]. Therefore, we investigated the
effects of melphalan, VP-16 and rTGF-b1 on the ability of HOB
to support CD34+ hematopoietic stem/progenitor cell selfrenewal and lineage differentiation. Figure 2A summarizes
observations indicating that following exposure to rTGF-b1 or
melphalan, distinct differentiation patterns of CD34+ bone
marrow cells were observed. Deficits in total lymphocytes, with
specific alteration of B cell and NK cell differentiation were
observed following co-culture with damaged HOB. T-cells
represented 0.1% of the lymphocyte cell population in the
untreated group, while no T cells were detected in cultures that
included HOB treated with rTGF-b1 or melphalan (data not

Figure 2. Melphalan or rTGF-b1 exposure diminished the ability of HOB to support CD34+ bone marrow cells. A) To evaluate HOB
support of CD34+ bone marrow cells, HOB cells were exposed to melphalan [25 mg/ml] or rTGF-b1 [10 ng/ml] for 24 hours. After the 24 hour
exposure, the HOB were thoroughly rinsed and CD34+ cells (8.86105) were added in co-culture. Recombinant IL-3 (100 ng/ml) was added in all
groups. CD34+ cells were collected after co-culture for 48 hours and the samples were analyzed for the expression of cell surface markers. B) HOB
were exposed to melphalan [50 mg/ml] or rTGF-b1 [10 ng/ml] for 24 hours. The HOB layers were rinsed and CD34+ bone marrow cells (1.756105)
were added in co-culture for 48 hours. The CD34+ cells were collected from the HOB layers, viability determined, and 16103 viable CD34+ bone
marrow cells were added to methocult containing factors for myeloid lineage in triplicate. Colonies were counted and scored after 7 days in culture.
*p,0.05 (average number of colonies, treated vs untreated), **p,0.05 (CFU-GM colonies, treated vs untreated) and #p,0.05 (CFU-M colonies,
treated vs untreated).
doi:10.1371/journal.pone.0030758.g002
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shown). Additionally, melphalan exposure of HOB led to a
decreased granulocyte population relative to total cell numbers,
while exposure to rTGF-b1 enhanced granulocyte differentiation.
Both rTGF-b1 and melphalan exposure decreased erythrocyte
progenitors. There was no change in monocytes with rTGF-b1
pre-exposure of HOB layers and a slight decrease in monocytes
with melphalan pre-exposure (data not shown). Viability among all
groups was similar (82–87%) and the total number of CD34+
blasts was comparable between all treatment groups.
To evaluate the ability of damaged HOB to support
hematopoietic progenitors, HOB were exposed to melphalan or
rTGF-b1, rinsed and CD34+ bone marrow cells were added in coculture, and colony assays completed. We determined that
melphalan and rTGF-b1 pre-exposure of HOB led to significant
decreases in colony forming units-granulocyte macrophage (CFUGM) and colony forming units-monocyte (CFU-M) colonies
formed from CD34+ progenitor cells.

borders. In contrast, there were increased numbers of differentiated colonies, defined by irregular borders, on coverslips where
colonies were grown on HOB layers exposed to melphalan, VP-16
or rTGF-b1.
Alterations in HOB function after aggressive treatment could
impact transplant engraftment and hematopoietic reconstitution
[8,24]. We utilized well characterized non-adherent CXCR-4+/
VLA-4+ C1.92 and JM-1 pro-B cells as a tool to investigate the
effects of chemotherapeutic agents or rTGF-b1 on the ability of
HOB to support immature hematopoietic progenitor cell adhesion. Experiments summarized in Figure 3C indicate that
following HOB exposure to chemotherapeutic agents or rTGFb1, C1.92 pro-B cells do not adhere as efficiently as they do to
HOB layers not exposed to those agents. To determine if
alterations in adhesion molecule expression were associated with
decreased adhesion between C1.92 and HOB, VCAM-1, CD44
and hyaluronan expression were evaluated on the HOB in the
presence and absence of exposure to chemotherapeutic agents or
rTGF-b1. No modulation of these proteins was detected on the
HOB during exposure to these agents (data not shown).

Exposure of HOB to chemotherapeutic agents or rTGF-b1
diminishes HOB support of human embryonic stem cells
and adhesion of pro-B cells

HOB expression of CXCL-12 is diminished following
exposure to chemotherapeutic agents or rTGF-b1

Based on the previous data describing altered support of
hematopoietic progenitors, we also investigated how chemotherapeutic agents or rTGF-b1 modulated the ability of HOB to
support human embryonic stem cells as an additional read out of
altered HOB function. To evaluate markers of pluripotent
potential, Oct-4 staining was completed on embryonic stem cell
colonies co-cultured with HOB pre-exposed to chemotherapeutic
agents or rTGF-b1. Oct-4 staining decreased in those colonies
grown on HOB exposed to the different agents (Figure 3A). Data
shown in Figure 3B suggests that healthy HOB have the ability to
support undifferentiated stem cell colonies characterized by
morphology of dense round colonies with definitive, regular cell

Inhibition of CXCL-12 in the bone marrow has been shown to
have a negative impact on chemotaxis coincident with deficits in
HSC homing and engraftment [18,32]. To further investigate the
impact of melphalan, VP-16 or rTGF-b1 exposure on expression
of HOB derived CXCL-12, real time RT-PCR and ELISA were
completed as described. Exposure of HOB to chemotherapeutic
agents or rTGF-b1 decreased the amount of CXCL-12 mRNA
and protein detected by real time RT-PCR and ELISA,
respectively (Figure 4A and B). Jung et al. have described the
regulation of CXCL-12 expression in HOB and the effect on

Figure 3. Exposure of HOB to chemotherapeutic agents or rTGF-b1 diminished the ability of HOB to support human embryonic
stem cells and decreased pro-B cell interaction with HOB. A) HOB were pre-exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1
[10 ng/ml] for 24 hours. The HOB were rinsed thoroughly and human embryonic stem cells were added in co-culture with the HOB. After 2 days of
co-culture, stem cell colonies were counted, stained for Oct-4 as an indicator of pluripotent potential and B) designated as undifferentiated or
differentiated based on classic morphology of well defined borders. C) To determine if exposure of HOB to chemotherapeutic agents or rTGF-b1
affected pro-B cell adherence, HOB were exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for 24 hours. Adherent layers of HOB
were rinsed thoroughly and co-cultured with fluorescently labeled pro-B cells (16105). After 24 hours the media was aspirated and non-adherent proB cells were gently rinsed. Remaining HOB and pro-B cells adherent to the HOB layer were trypsinized and events counted on high flow rate for
30 seconds to enumerate number of pro-B cells attached to the HOB. *p,0.05.
doi:10.1371/journal.pone.0030758.g003
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Figure 4. Exposure of HOB to chemotherapeutic agents or rTGF-b1 decreased the expression of CXCL-12 and diminished support of
pro-B cell chemotaxis. A) HOB were exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for 24 hours. RNA was isolated and
real time RT-PCR completed for CXCL-12. B) HOB were exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for 24 hours.

PLoS ONE | www.plosone.org

7

February 2012 | Volume 7 | Issue 2 | e30758

Niche Damage by Chemotherapeutic Agents

Following exposure, cells were rinsed and new media added and conditioned for 48, 72 or 96 hours. Supernatants were collected and evaluated by
CXCL-12 ELISA. C) HOB were exposed to melphalan [50 mg/ml], VP-16 [50 mM] or rTGF-b1 [10 ng/ml] for 24 hours. Following exposure, 350 ul of
supernatant was placed into the bottom chamber of a transwell with or without CXCL-12 [1 ng/ml]. HOB media and CXCL-12 [100 ng/ml] were used
as negative and positive controls, respectively. JM-1 progenitor cells (1.56105) were placed in the top chamber and allowed to migrate for 4 hours.
After 4 hours, the cells migrating to the bottom chamber were read on high flow rate for 30 seconds on a FACSCalibur flow cytometer.
(CM = conditioned media), *p,0.05 (CM compared to treatments), #p,0.05 (individual group compared to CXCL-12 addition).
doi:10.1371/journal.pone.0030758.g004

ment is critical for hematopoietic recovery. Earlier reports have
suggested that BMSC are vulnerable to functional damage
imposed by aggressive chemotherapeutic agents [16,17,36]. These
studies have focused largely on the ability of stromal cells to
generate fibroblastic colonies (CFU-F) or to support survival or
expansion of committed progenitor cells when isolated from
patients following drug exposures [37].
Murine models of ablative treatment and stem cell transplantation have shown long-term deficits in hematopoietic recovery
and in vitro models have paralleled these studies documenting the
inability of transplanted cells to migrate efficiently to the
anatomical niches necessary for engraftment [38]. Observations
of long-term hematopoietic deficits in the bone marrow of
transplantation patients suggest that the functionality of the
developmental niches required for appropriate support of
immature hematopoietic or stem cells may have be compromised
by aggressive pre-transplant therapies. One study observed that at
1 year post transplant 61% of patients had subnormal values in
one or more hematopoietic lineages [39]. Furthermore, Nieboer et
al. showed that at 5 years post transplant 15% of the patient
population analyzed had low values in one or more hematopoietic
cell lineages [40]. Investigations of the mechanisms that underlie
damage of the hematopoietic and stem cell niches are further
encouraged by retrospective studies of patients that received
allogeneic bone marrow transplants in which patient HSC
numbers did not recover to the levels of control patients, even
after 12 years, as measured by CFU-F frequencies, suggesting that
the damage of the structural, hematopoietic supportive cells of the
bone marrow can be sustained [41].
In the current study we characterized the impact of direct and
indirect damage on HOB and their subsequent ability to support
progenitor and stem cells. Following transplantation and during
development, HSC home to the endosteal niche which acts as a
critical regulator of stem cell quiescence, proliferation, and
conservation of the stem cell pool. This stem cell pool also
provides all the cells necessary for hematopoietic reconstitution
and recovery. Direct contact between HOB and HSC is required
for HSC survival [7,8,42] with a dynamic relationship demonstrated by the ability of HSC to regulate the cytokines expressed by
HOB in order to enhance their own survival. Studies by Calvi et
al., and others, have shown that number the of osteoblasts present
in the niche directly modulates the numbers of HSC supported by
the niche [7,8,24].
Our data shows that direct exposure to chemotherapeutic
agents increases the activity of HOB derived TGF-b1, one of the
known negative regulators of HSCs (Figure 1) [15–17]. Consistent
with the literature suggesting that TGF-b activity leads to
decreased expression of HSC surface cytokine receptors and a
deficit in the stem cell pool [17,43], Figure 2 summarizes data
showing HOB pre-exposed to either melphalan or rTGF-b1 had a
decreased ability to support appropriate differentiation of CD34+
bone marrow cells. Alterations occurred in the lymphocyte
population, with decreased B cells, NK cells and T cells. In
addition there were decreased erythroid and granulocyte progenitors derived from CD34+ cells co-cultured with pre-exposed
HOB. The total CD34+ blast population was similar between all

homing and reported that treatment of HOB with TGF-b
decreased CXCL-12 secretion, consistent with our results [33].
Additionally, as a functional readout of a potential CXCL-12
deficit in our model, chemotaxis assays were completed. Figure 4C
summarizes data indicating that the chemotaxis of JM-1 cells
toward adherent layers of HOB was impaired following preexposure of HOB to melphalan, VP-16 and rTGF-b1. The
addition of CXCL-12 [1 ng/ml] to the media of HOB preexposed to chemotherapeutic agents or rTGF-b1 prior to the start
of the assay restored the chemotaxis of JM-1 cells. As an additional
control, AMD-3100, a CXCR-4 inhibitor, was used to confirm
that pre-incubation of JM-1 cells with AMD-3100 prior to the start
of chemotaxis inhibited migration towards both rCXCL-12 as well
as media conditioned by HOB (data not shown).

Direct and indirect exposure to chemotherapeutic agents
or rTGF-b1 results in global changes in HOB gene
expression
To elucidate the global changes that occur in HOB with direct
and indirect insult from chemotherapeutic agents or rTGF-b1,
HOB were exposed to melphalan or rTGF-b1. In addition, HOB
were exposed to conditioned media from BMSC that had been
pre-exposed to melphalan (drug removed prior to collection of
conditioned media) to recapitulate signaling that may occur in
response not only to active TGF-b1 elaborated by BMSC, but also
in response to the collective soluble factors elaborated by BMSC in
response to stress induced by chemotherapeutic agents. Microarray analysis of gene expression was performed as described. The
genes for which expression changed in each group individually,
and common gene targets that overlap between treatment groups,
are indicated in the Venn diagram (Figure 5A). HOB exposure to
rTGF-b1 resulted in the highest number of genes influenced across
the groups evaluated, with melphalan exposure also resulting in a
robust effect. Twenty-five common genes significantly changed
when the intersection of all treatment groups was considered. The
Venn and network diagrams show the number of genes modulated
in response to exposure to melphalan or rTGF-b1, and potential
relationships between some of the responsive genes, as well as
convergence on signaling molecules such as the NF-kB complex
which emerged as a hub of signaling (Figure 5B). The genes that
were commonly up-regulated (red) or down-regulated (green)
between treatment groups are shown and include: 4 up-regulated,
2 down-regulated (Figure 5C, intersection of all 3 treatments), 16
up-regulated, 3 down-regulated (Figure S1, CMM: melphalan), 26
up-regulated, 11 down-regulated (Figure S2, rTGF:CMM), and 97
up-regulated, 188 down-regulated (Figure S3, rTGF: melphalan).
This summary can be compared with those genes that were
influenced, but in opposing directions, between groups (Table S1).

Discussion
Myelosuppressive and ablative therapies followed by stem cell
transplantation is used to treat hematopoietic, breast, ovarian and
brain tumors as well as childhood sarcomas, and immune
deficiencies [34,35]. As the primary site of postnatal hematopoiesis, the functional integrity of the bone marrow microenvironPLoS ONE | www.plosone.org
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Figure 5. Global changes in gene expression in HOB following direct and indirect exposure to chemotherapeutic agents or rTGF-b1.
HOB cells were exposed to melphalan [50 mg/ml], rTGF-b1 [10 ng/ml] or conditioned media from BMSC (CMM) pre-exposed to melphalan [50 mg/ml24 hours] for 6 hours. BMSC exposed to melphalan were rinsed and fresh media was place on adherent layers to condition prior to stimulating HOB.
After the 6 hour exposure, HOB RNA was isolated and microarray analysis completed to evaluate global changes in gene expression. A) The Venn
diagram summarizes the number of HOB genes that changed within each group as well as the changes between the groups. B) A network diagram
was generated for the intersection of all 3 treatment groups highlighting the convergence of potential pathways associated with the genes found in
common between the 3 treatment groups, such as NF-kB. All genes listed were generated using a 2.5% FDR and .1.5 fold change in significance. C)
A gene summary was made common genes up-regulated (4, red) or down-regulated (2, green) for the intersection of all 3 treatments (rTGF-b1: CMM:
melphalan).
doi:10.1371/journal.pone.0030758.g005

three treatment groups, suggesting damage induced by chemotherapeutic agents may predominately alter HOB modulation of
hematopoietic cell differentiation. We also observed that CD34+
PLoS ONE | www.plosone.org

bone marrow cells co-cultured with HOB exposed to melphalan or
rTGF-b1 had decreased hematopoietic potential when evaluated
by a colony assay with an overall decrease in colony number,
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specifically CFU-GM and CFU-M colonies. Interestingly, it was
observed that BFU-E colony formation was not significantly
altered, while surface staining showed decreased erythroid
progenitors. This suggests that the more differentiated erythroid
cells may be affected by damaged microenvironment components,
while the more primitive erythroid precursors are spared. Figure 3
provides additional evidence that damaged HOB have a decreased
ability to interact with, and support, both human embryonic stem
cells as well as more differentiated pro-B cells. Direct treatment of
HOB with chemotherapeutic agents or rTGF-b1 resulted in a
reduction of pro-B cell adhesion as well as a diminished ability to
support Oct-4 positive embryonic stem cells.
An important consideration when evaluating the dynamic
balance of the niche is the role of adhesion molecules physically
tethering progenitor cells to supportive cells of the bone marrow,
providing signals for their maturation and survival. Earlier reports
have described the role of the VCAM-1/VLA-4 interaction in
hematopoiesis. Ryan et al. demonstrated that adhesion of B-cell
precursors to BMSC was dependent on this interaction and Dittel
et al. elucidated how cytokines could alter the surface expression of
VCAM-1 [44,45].
In addition to the VCAM-1/VLA-4 interaction, the CD44/
hyaluronan (HA) interaction has also been recognized for its role
in hematopoiesis and homing of primitive cells to the bone marrow
[46]. Avigdor et al. demonstrated the important roles of CXCL-12
with respect to migration and anchoring of progenitors to the bone
marrow through CD44/HA [47].. It was based on these
observations that we investigated the effects of chemotherapeutic
agents on VCAM-1, CD44, and HA in our model of HOB
damage. Figure 3C shows that pro-B cells co-cultured with HOB
pre-exposed to melphalan, VP-16 or rTGF-b1 are unable to
adhere to the HOB efficiently. However, investigation of the
adhesion molecules VCAM-1, CD44 and HA indicated no altered
expression following exposure to chemotherapeutic agents or
rTGF-b1 (data not shown). These observations suggest that the
deficit in hematopoietic support, in our model, may be the result of
changes in a soluble factor acting in either an autocrine or
paracrine manner to diminish optimal cell-cell interactions or that
an unidentified adhesion molecule is influenced by the chemotherapeutic agents evaluated. Paracrine effects could be modulated, in part, through alteration of integrin activity, which would not
have been detected in our assay. These observations also suggest
very specific effects of chemotherapeutic agents on BMSC and
HOB components of the niche, emphasizing the need to
understand each population individually to understand the total
response of the niche to therapy.
We next examined the effect of chemotherapeutic agents or
rTGF-b1 on HOB derived CXCL-12. Data in Figure 4A and B
shows that melphalan, VP-16 and rTGF-b1 decreased CXCL-12
mRNA and protein expression in HOB. Jung et al. have
previously shown that CXCL-12 secreted by HOB may
contribute to stem cell homing [48]. Decreased CXCL-12 in
the microenvironment due to chemotherapy damage of HOB
may affect hematopoietic reconstitution. The decrease in CXCL12 protein expression correlated with decreased chemotaxis of
CXCR-4+ JM-1 cells towards HOB pre-exposed to melphalan,
VP-16 or rTGF-b1. The decrease in chemotaxis was restored
with the addition of CXCL-12, provide further evidence that
damage to HOB may affect stem cell homing. CXCL-12 is not
the only factor critical for homing and further investigation of
other factors, including stem cell factor (SCF), which has been
shown to synergize with CXCL-12 in homing of stem cells and
retention in their developmental niche need to be investigated
[49].
PLoS ONE | www.plosone.org

Collectively, these data suggest that generation of active TGFb1 in the endosteal niche can negatively affect production of
CXCL-12, thus impairing progenitor cell homing to the bone
marrow, and subsequent engraftment, and reconstitution of the
patient’s immune system. This observation of altered gene
expression in HOB resulting from exposure to chemotherapeutic
agents prompted us to use microarray analysis to investigate the
magnitude of direct and indirect damage to HOB induced by
exposure to melphalan or rTGF-b1. After 6 hours of exposure to
those agents, the diverse changes observed in HOB gene
expression alone allow for a better understanding of the
significance of the potential damage to the niche and the
subsequent impact on hematopoietic reconstitution that relies on
balanced expression of several proteins. Interestingly, exposure of
HOB to rTGF-b1, melphalan and conditioned media from
melphalan pre-exposed BMSC all identified NF-kB as a point of
convergence (Figure 5B). As with all gene expression pathway
analysis, in the absence of targeted genetic manipulation or
biochemical analysis, the interactions remain hypothetical. The
most pronounced value of these data in the current study is to
provide a sense of the responsiveness of HOB to genotoxic stress,
as well as to factors such as TGF-b1, which may participate in
both autocrine and paracrine signaling in the bone marrow niche.
Points of convergence, such as NF-kB, may then provide the focus
for a more mechanistic investigation of cell signaling downstream
of stress in the bone marrow microenvironment. Of relevance to
the current investigation, subsequent real-time PCR analyzing
RUNX2, alkaline phosphatase, collagen 1A1 and osteocalcin
demonstrated distinct responses to melphalan and VP-16
exposure. The most consistent changes observed in pilot studies
were decreases in RUNX2 and collagen 1A1, with the most
pronounced reduction for genes observed following melphalan
exposure (data not shown). No consistent change in osteocalcin or
alkaline phosphatase was noted. The potential influence of dose
escalated chemotherapy on osteoblast differentiation is currently
under further investigation by our group.
Central to our investigation was an interest in the influence of
active TGF-b1 released from HOB exposed to chemotherapeutic
agents as well as TGF-b1 that may be released from neighboring
BMSC in a damaged microenvironment as just two potential
sources of this growth factor. Studies by Batard et al. have
described the importance of low levels of TGF-b1 in the bone
marrow microenvironment for maintenance of the stem cell pool
through up-regulation of the CD34 antigen, a marker of primitive
HSC [43]. Consistent with the need for rigorous control of total
TGF-b1 levels, a number of studies have shown the benefit of
TGF-b neutralization during therapy [50]. Lagneaux et al. showed
that stromal cells isolated from B-CLL patients had increased
TGF-b production correlating with decreased colony-stimulating
activity which was corrected by neutralizing TGF-b activity [17].
Using a murine model of breast cancer, Biswas et al. showed that
radiation or doxorubicin treatment increased levels of TGF-b
which correlated with increased circulating tumor cells and
increased metastasis [51]. These effects were abrogated by antiTGF-b antibodies, providing rationale for utilization of TGF-b
inhibitors, such as GC1008, which is currently in clinical trials in
the setting of renal cell carcinoma and malignant melanoma [52].
Based on our observations, application of TGF-b neutralizing
antibodies may have utility through influence on both hematopoietic cells and the niche in which they develop.
Our observations indicate that HOB are susceptible to
genotoxic stress documented by alteration of gene expression
profiles (Figure 5, Figure S1, S2, S3, Table S1) and functional
deficits in hematopoietic cell support, including differentiation and
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hematopoietic potential (Figure 2). Further investigation will
identify targets that may prove useful in augmenting hematopoietic recovery through ‘‘balancing’’ the stem cell niche following
therapy-induced damage. Long-term hematopoietic deficits may
be derived from the immediate changes in the niche that are
imposed by aggressive therapeutic regimens. This aspect of altered
bone marrow function following exposure to chemotherapeutic
agents may highlight an area in which a better understanding of
HOB damage by genotoxic agents may identify new therapeutic
strategies to augment efficient patient recovery following bone
marrow transplantation.

decreased (11, green). B) A network diagram was generated for the
intersection of TGF-b:CMM groups that highlights the convergence of potential pathways between these 2 treatment groups. All
genes listed were generated using a 2.5% FDR and 1.5 fold
significant cut off.
(PDF)
Figure S3 rTGF-b exposure induces HOB gene expres-

sion changes in common with those subsequent to
melphalan exposure. HOB cells were treated for 6 hours with
10 ng/ml rTGF-b, or with 50 mg/ml melphalan for 24 hours.
After the 6 hour treatment, HOB RNA was isolated and
microarray analysis was completed to evaluate global changes in
gene expression. A) Gene changes for the intersections of the TGFb:melphalan groups were analyzed based on the genes that
commonly increased (97, red) or decreased (188, green). B) A
network diagram was generated for the intersection of TGF-b:
melphalan groups that highlights the convergence of potential
pathways between these 2 treatment groups. All genes listed were
generated using a 2.5% FDR and 1.5 fold significant cut off.
(PDF)

Supporting Information
Figure S1 Soluble factors in BMSC exposed to chemotherapy induce HOB gene expression changes in common with those subsequent to melphalan exposure. HOB
cells were treated for 6 hours with 50 mg/ml melphalan, or
conditioned media from BMSC pre-treated with 50 mg/ml
melphalan for 24 hours. BMSC exposed to melphalan were
rinsed and fresh media was place on adherent layers to condition
and to remove drug prior to stimulating HOB. After the 6 hour
treatment, HOB RNA was isolated and microarray analysis was
completed to evaluate global changes in gene expression. A) Gene
changes for the intersections of the CMM:melphalan groups were
analyzed based on the genes that commonly increased (16, red) or
decreased (3, green). B) A network diagram was generated for the
intersection of CMM:melphalan groups that highlights the
convergence of potential pathways between these 2 treatment
groups. All genes listed were generated using a 2.5% FDR and 1.5
fold significant cut off.
(PDF)

Table S1 Global changes occur in gene expression with
direct and indirect chemotherapy treatment. Complete
lists of genes modified, in the same or opposite directions, in
response to treatment for each intersection group are shown
(CMM:melphalan, CMM:TGF, TGF:melphalan, Intersection of
all 3) with fold changes and confidence intervals (C.I.). All genes
listed were generated using a 2.5% FDR and 1.5 fold significant
cut off.
(XLS)
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